DUBLIN--(BUSINESS WIRE)--The 'Peptide Drug Conjugates Market Size, Share & Trends Analysis Report By Product (Lutetium, Melflufen, ANG1005, BT1718, CBX-12, Other Pipeline), By type (Diagnostic, Therapeutic), By Region, And Segment Forecasts, 2023 - 2030' report has been added to ResearchAndMarkets.com's offering..

都柏林-（商业线）--“肽-药物结合市场规模，份额和趋势分析报告副产品（Lutetium，Melflufen，ANG1005，BT1718，CBX-12，其他管道），按类型（诊断，治疗）），按地区和细分预测，2023年至2030年的报告已添加到ResearchAndMarkets.com的产品中。。

The global peptide drug conjugates market is poised for significant growth, with an expected value of USD 4.21 billion by 2030, registering a remarkable Compound Annual Growth Rate (CAGR) of 28.58% during the forecast period.

全球肽-药物结合市场有望实现显着增长，到2030年预期价值为42.1亿美元，预计期间复合年增长率（CAGR）显着为28.58%。

Key Market Drivers:

主要市场驱动因素：

Rising Cancer Cases: The market's growth is driven by the global surge in cancer cases and related mortality. According to the World Health Organization (WHO), cancer is the leading cause of disease-related deaths worldwide, with over 10.0 million deaths recorded globally in 2020 and more than 6.0 million deaths in the U.S.

癌症病例上升：市场的增长是由全球癌症病例和相关死亡率激增所驱动的。根据世界卫生组织（WHO）的数据，癌症是全球疾病相关死亡的主要原因，2020年全球死亡人数超过1000万，美国死亡人数超过600万。

By 2040, it is estimated that there will be 29.0 million new cancer cases and 16.0 million cancer-related deaths per year. The increasing demand for novel treatments like peptide drug conjugates (PDCs) to target uncontrolled cell growth is expected to fuel market growth..

到2040年，估计每年将有2900万新的癌症病例和1600万癌症相关死亡病例。对肽-药物偶联物（pDC）等新型治疗方法的需求日益增长，以针对不受控制的细胞生长，预计将推动市场增长。。

FDA-Approved PDCs: Currently, two FDA-approved PDCs are available for the treatment of uncontrolled cell growth. Novartis's Lutathera (lutetium Lu 177) is indicated for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults, while Oncopeptides AB's Pepaxto (Melphalan) received accelerated approval by the FDA for the treatment of multiple myeloma in February 2021.

FDA批准的pDC：目前，两种FDA批准的pDC可用于治疗不受控制的细胞生长。诺华公司的Lutathera（lutetium Lu 177）适用于成人生长抑素受体阳性的胃肠胰腺神经内分泌肿瘤，而Oncopeptides AB的Pepaxto（美法仑）于2021年2月获得FDA加速批准用于治疗多发性骨髓瘤。

The limited number of FDA-approved PDCs presents a lucrative opportunity for market growth..

FDA批准的pDC数量有限，为市场增长提供了有利可图的机会。。

Robust Clinical Trial Pipeline: The presence of a robust clinical trial pipeline and the expected launch of new PDCs are anticipated to boost market growth. PDCs such as ANG1005, BT5528, and BT1718 are undergoing phase 2 and phase 3 clinical studies for the treatment of brain tumors and lung cancer.

强大的临床试验流程：强大的临床试验流程的存在以及预计推出的新型pDC将促进市场增长。诸如ANG1005，BT5528和BT1718的PDC正在进行用于治疗脑肿瘤和肺癌的2期和3期临床研究。

CBX-12, another phase 2 PDC candidate, is indicated for the treatment of small cell lung cancer..

CBX-12是另一种2期PDC候选药物，适用于治疗小细胞肺癌。。

Strategic Initiatives: Key players in the market are actively undertaking strategic initiatives such as collaborations, mergers & acquisitions, agreements, and financial investments, which are driving market growth. For instance, in December 2021, Coherent Biopharma and WuXi STA announced a strategic partnership agreement to develop their current and future therapeutic drugs, including peptide drug conjugates..

战略举措：市场主要参与者正在积极开展战略举措，如合作，兼并，协议和金融投资，这些都在推动市场增长。例如，2021年12月，Coherent Biopharma和无锡STA宣布了一项战略合作协议，以开发其当前和未来的治疗药物，包括肽-药物偶联物。。

Companies Mentioned

公司提到

Novartis Ag.

诺华公司。

Bicycle Therapeutics

自行车疗法

Astrazeneca

阿斯利康

Cybrexa Therapeutics

Cybrexa疗法

Oncopeptides Inc.

Oncopeptides公司。

Angiochem Inc.

Angiochem股份有限公司。

Innovasium Soricimed Biopharma

Innovasium Soricimed生物制药

Theratechnologies

技术

Peptide Drug Conjugates Market Report Highlights:

肽-药物偶联物市场报告重点：

Lutathera Dominates: In 2022, the Lutathera segment accounted for the largest share of the market due to its status as the first approved PDC and the global rise in cancer patients, resulting in high demand for these medicines.

Lutathera占主导地位：2022年，Lutathera细分市场占有最大份额，因为它是第一个获得批准的PDC，并且癌症患者全球崛起，导致对这些药物的高需求。

Therapeutic Segment Leads: In 2022, the therapeutic segment dominated the peptide drug conjugates market, primarily due to the presence of both approved PDCs, Lutathera and Pepaxto, as therapeutic agents targeting tumor cells.

治疗部分导致：2022年，治疗部分主导肽-药物偶联物市场，主要是由于存在批准的pDC，Lutathera和Pepaxto，作为靶向肿瘤细胞的治疗剂。

North America Takes the Lead: North America led the global market in 2022, driven by factors such as an increase in new cancer cases, complexity related to cancer, and high awareness among healthcare professionals about novel therapies

北美领先：北美在2022年引领全球市场，受新癌症病例增加，癌症相关复杂性以及医疗保健专业人员对新疗法的高度认识等因素驱动

Key Topics Covered:

涵盖的主要主题：

Chapter 1 Methodology and Scope

第1章方法和范围

Chapter 2 Executive Summary

第2章执行摘要

Chapter 3 Peptide Drug Conjugates Market Variables, Trends, and Scope

第3章肽-药物结合物市场变量，趋势和范围

3.1 Peptide Drug Conjugates Market Lineage Outlook

3.1肽-药物偶联物市场谱系展望

3.1.1 Parent Market Outlook

3.1.1母市场前景

3.2 Market Dynamics

3.2市场动态

3.2.1 Market Driver Analysis

3.2.1市场驱动因素分析

3.2.1.1 Rising Cancer Prevalence and Related Mortality

3.2.1.1癌症患病率和相关死亡率上升

3.2.1.1.1 Cancer Incidence Data

3.2.1.1.1癌症发病率数据

3.2.1.2 Robust Clinical Trial Pipeline

3.2.1.2强大的临床试验流程

3.2.2 Market Restraint Analysis

3.2.2市场约束分析

3.2.2.1 Long R&D Time and Slow Clinical Development Process

3.2.2.1研发时间长，临床开发过程缓慢

3.3 Peptide Therapeutics Market Analysis Tools

3.3肽疗法市场分析工具

3.3.1 Porter's Five Forces Analysis

3.3.1波特的五力分析

3.3.2 PESTLE Analysis

3.3.2杵分析

3.4 Pipeline Analysis

3.4管道分析

Chapter 4 Peptide Drug Conjugates Market - Segment Analysis, by Type, 2018 - 2030 (USD Million)

第4章肽-药物偶联物市场-细分分析，按类型，2018-2030（百万美元）

Chapter 5 Peptide Drug Conjugates Market - Segment Analysis, by Product, 2018 - 2030 (USD Million)

第5章肽-药物偶联物市场-细分分析，副产品，2018-2030年（百万美元）

Chapter 6 Peptide Drug Conjugates Market: Regional Estimates and Trend Analysis by Product and Type, 2018 - 2030 (USD Million)

第6章肽-药物偶联物市场：按产品和类型进行的区域估计和趋势分析，2018-2030年（百万美元）

Chapter 7 Competitive Landscape

第七章竞争格局

Chapter 8 Conclusion

第8章结论

For more information about this report visit https://www.researchandmarkets.com/r/rc8pfe

有关此报告的更多信息，请访问https://www.researchandmarkets.com/r/rc8pfe

About ResearchAndMarkets.com

关于ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com是国际市场研究报告和市场数据的全球领先来源。我们为您提供有关国际和区域市场，关键行业，顶级公司，新产品和最新趋势的最新数据。